Exhibits coproporphyrinogen oxidase activity and identical protein binding activity. Involved in several processes, including protoporphyrinogen IX biosynthetic process; response to lead ion; and response to methylmercury. Localizes to mitochondrial inner membrane and mitochondrial intermembrane space. Human ortholog(s) of this gene implicated in hereditary coproporphyria and liver disease. Orthologous to human CPOX (coproporphyrinogen oxidase); PARTICIPATES IN acute intermittent porphyria pathway; erythropoietic porphyria pathway; heme biosynthetic pathway; INTERACTS WITH 2,6-dinitrotoluene; bisphenol A; finasteride.
AHR protein inhibits the reaction [Benzoapyrene results in decreased expression of CPOX mRNA], AHR protein inhibits the reaction [Benzoapyrene results in increased expression of CPOX mRNA]
[Clofibrate co-treated with Acetaminophen] affects the expression of CPOX mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CPOX mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CPOX mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of CPOX mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CPOX mRNA]
Mercury inhibits the reaction [CPOX protein results in increased chemical synthesis of protoporphyrinogen], TGFB1 protein promotes the reaction [CPOX protein results in increased chemical synthesis of protoporphyrinogen]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CPOX mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CPOX mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin